Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies

mAbs

Volumn 6, Issue 5, 2014, Pages 1300-1313

  Winiarska, Magdalena ^a   Bojarczuk, Kamil ^a   Pyrzynska, Beata ^a   Bil, Jacek ^a,b   Siernicka, Marta ^a   Dwojak, Michal ^a   Bobrowicz, Malgorzata ^a   Miazek, Nina ^a   Zapala, Piotr ^a   Zagozdzon, Agnieszka ^a,c   Krol, Magdalena ^d   Syta, Aleksra ^a   Podszywalow Bartnicka, Paulina ^e   Pilch, Zo Fia ^a   Dabrowska Iwanicka, Anna ^f   Juszczynski, Przemyslaw ^g   Efremov, Dimitar G ^h   Slabicki, Mikolaj ⁱ   Zenz, Thorsten ⁱ   Roy, Aude Le ^j   Olive, Daniel ^j   Rygiel, Tomasz P ^a   Leusen, Jeanette H W ^k   Golab, Jakub ^a,l   more..

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^c BTM Mazowsze ^*  (Poland)

^d WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^e NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^h INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j AIX MARSEILLE UNIVERSITY   (France)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l INSTITUTE OF PHYSICAL CHEMISTRY   (Poland)

more..

Author keywords

CD20; Dasatinib; Ofatumumab; Rituximab; Src family kinases

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALEMTUZUMAB; BAFETINIB; DASATINIB; EVEROLIMUS; OFATUMUMAB; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE; HUMAN; HUMAN CELL; MOUSE; MS4A1 GENE; NATURAL KILLER CELL; NONHUMAN; PRIMARY TUMOR; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84913591281     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.32106     Document Type: Article

References (52)

1. Yamanashi Y, Kakiuchi T, Mizuguchi J, Yamamoto T, Toyoshima K. Association of B cell antigen receptor with protein tyrosine kinase Lyn. Science 1991; 251:192-4; PMID:1702903; http://dx.doi.org/10.1126/ science.1702903
2. Burkhardt AL, Brunswick M, Bolen JB, Mond JJ. Antiimmunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proc Natl Acad Sci U S A 1991; 88:7410-4; PMID:1714601; http://dx.doi.org/10.1073/pnas.88.16.7410
3. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115:369-78; PMID:15650771; http://dx.doi.org/ 10.1172/JCI200522094
4. Tauzin S, Ding H, Khatib K, Ahmad I, Burdevet D, van Echten-Deckert G, Lindquist JA, Schraven B, Din NU, Borisch B, et al. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood 2008; 111:2310-20; PMID:18070987; http://dx.doi.org/10.1182/blood-2007-05-090985
5. Packard TA, Cambier JC. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. F1000Prime Rep 2013; 5:40; PMID:24167721; http://dx.doi.org/10.12703/P5-40
6. Li S. Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin Ther Targets 2005; 9:329-41; PMID:15934919; http://dx.doi.org/ 10.1517/14728222.9.2.329
7. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735
8. Bil J, Winiarska M, Nowis D, Bojarczuk K, Dabrow-ska-Iwanicka A, Basak GW, Sułek K, Jakobisiak M, Golab J. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated comple-ment-dependent cytotoxicity. Blood 2010; 115:3745-55; PMID:20200358; http://dx.doi.org/10.1182/ blood-2009-09-244129
9. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008; 5:e64; PMID:18366248; http://dx. doi.org/10.1371/journal.pmed.0050064
10. Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 2011; 187:3438-47; PMID:21841127; http://dx.doi. org/10.4049/jimmunol.1101189
11. Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 2014; 28:1163-7; PMID:24492323; http://dx.doi. org/10.1038/leu.2014.12
12. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70:3209-17; PMID:20354182; http://dx.doi.org/10.1158/0008-5472.CAN-09-4109
13. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463:88-92; PMID:20054396; http://dx.doi.org/10.1038/ nature08638
14. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111:2230-7; PMID:18006696; http://dx.doi.org/10.1182/blood-2007-07-100115
15. Thévenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993; 268:5949-56; PMID:7680653
16. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28-39; PMID:19104514; http://dx.doi.org/ 10.1038/nrc2559
17. Peters EC, Gray NS. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem Biol 2007; 2:661-4; PMID:18041816; http:// dx.doi.org/10.1021/cb700203j
18. Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP, Ye F, Zhang D, Knowles DM, Wang YL. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008; 22:1755-66; PMID:18596745; http://dx.doi.org/10.1038/leu. 2008.163
19. Ke J, Chelvarajan RL, Sindhava V, Robertson DA, Lekakis L, Jennings CD, Bondada S. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol Cancer 2009; 8:132; PMID:20043832; http://dx.doi.org/10.1186/1476-4598-8-132
20. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270:22632-8; PMID:7545683; http://dx.doi.org/ 10.1074/jbc.270.38.22632
21. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP. Binding of submaximal C1q promotes complementdependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009; 183:749-58; PMID:19535640; http://dx.doi.org/ 10.4049/jimmunol.0900632
22. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013; 190:231-9; PMID:23225880; http://dx.doi.org/10.4049/ jimmunol.1202645
23. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12:4027-35; PMID:16818702; http://dx.doi.org/10.1158/1078-0432.CCR-06-0066
24. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111:4415-6; PMID:18398058; http://dx.doi.org/10.1182/blood-2008-02-138701
25. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4C and CD8 CT-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37:256-65; PMID:19056158; http://dx.doi.org/10.1016/j. exphem.2008.09.013
26. Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer 2012; 131:E916-27; PMID:22419518; http://dx.doi.org/10.1002/ijc.27537
27. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007; 104:13283-8; PMID:17684099; http://dx.doi.org/10.1073/pnas. 0702654104
28. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008; 111:3097-107; PMID:18180381; http://dx.doi.org/10.1182/blood-2007-08-104372
29. Seliem RM, Freeman JK, Steingart RH, Hasserjian RP. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol 2006; 14:18-23; PMID:16540725; http://dx.doi.org/10.1097/01. pai.0000145130.02931.74
30. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5:611-5; PMID:10100713
31. Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 2001; 114:881-3; PMID:11564080; http:// dx.doi.org/10.1046/j.1365-2141.2001.03019.x
32. Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106:571-2; PMID:10460626; http://dx.doi.org/10.1046/j.1365-2141.1999.01608.x
33. Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J Clin Oncol 1998; 16:3916; PMID:9850038
34. Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, Bazarbachi A. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003; 70:330-2; PMID:12694172; http:// dx.doi.org/10.1034/j.1600-0609.2003.00007.x
35. Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci 2009; 100:54-61; PMID:19038008; http://dx.doi.org/10.1111/j.1349-7006.2008.01005.x
36. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T. Downregulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009; 113:4885-93; PMID: 19246561; http://dx.doi.org/10.1182/blood-2008-08-175208
37. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102:3514-20; PMID:12893761; http://dx.doi.org/10.1182/blood-2003-01-0055
38. Pickartz T, Ringel F, Wedde M, Renz H, Klein A, von Neuhoff N, Dreger P, Kreuzer KA, Schmidt CA, Srock S, et al. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Exp Hematol 2001; 29:1410-6; PMID:11750099; http://dx.doi.org/ 10.1016/S0301-472X(01)00753-6
39. Ushmorov A, Leithäuser F, Sakk O, Weinhüsel A, Popov SW, Möller P, Wirth T. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107:2493-500; PMID:16304050; http://dx.doi.org/10.1182/ blood-2005-09-3765
40. Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M, Kinoshita T, Naoe T. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007; 86:49-57; PMID:17675267; http://dx.doi.org/ 10.1532/IJH97.07028
41. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009; 15:2523-30; PMID:19276251; http://dx.doi.org/10.1158/1078-0432.CCR-08-1403
42. Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leuk Res 2009; 33:792-7; PMID:19054557; http://dx. doi.org/10.1016/j.leukres.2008.10.013
43. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143-59; PMID:19620786
44. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176:2600-9; PMID:16456022; http:// dx.doi.org/10.4049/jimmunol.176.4.2600
45. Ringshausen I, Feuerstacke Y, Krainz P, den Hollander J, Hermann K, Buck A, Peschel C, Meyer Zum Bueschenfelde C. Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts. Cancer Res 2010; 70:4292-6; PMID:20460536; http://dx.doi.org/10.1158/0008-5472.CAN-10-0259
46. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123:1957-60; PMID:24652965; http://dx.doi.org/ 10.1182/blood-2014-01-547869
47. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370:997-1007; PMID:24450857; http://dx.doi. org/10.1056/NEJMoa1315226
48. Reeder CB, Ansell SM. Novel therapeutic agents for Bcell lymphoma: developing rational combinations. Blood 2011; 117:1453-62; PMID:20978267; http:// dx.doi.org/10.1182/blood-2010-06-255067
49. Winiarska M, Nowis D, Bil J, Glodkowska-Mrowka E, Muchowicz A, Wanczyk M, Bojarczuk K, Dwojak M, Firczuk M, Wilczek E, et al. Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complementdependent cytotoxicity. J Biol Chem 2012; 287:31983-93; PMID:22843692; http://dx.doi.org/10.1074/jbc. M112.374751
50. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581-7; PMID:12874252; http://dx.doi.org/10.4049/ jimmunol.171.3.1581
51. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010; 115:1406-15; PMID:20008787; http://dx.doi.org/10.1182/blood-2009-06-229443
52. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. Control of dendritic arborization by the phosphoinositide-30 -kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 2005; 25:11300-12; PMID:16339025; http://dx.doi.org/10.1523/ JNEUROSCI.2270-05.2005